Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease

Published:2020-01-15 Issue:1 Volume:14 Page:7-19
ISSN:1976-2283
Container-title:Gut and Liver
language:en
Short-container-title:Gut and Liver

Author:

Nakase Hiroshi¹

Affiliation:

1. Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan

Funder

Ministry of Health, Labour and Welfare of Japan

Japan Society for the Promotion of Science

Publisher

The Editorial Office of Gut and Liver

Subject

Gastroenterology,Hepatology

Link

http://pdf.medrang.co.kr/GNL/2020/014/GNL014-01-04.pdf

Reference77 articles.

1. Nakase H. How to select and use IBD drugs. Tokyo: Yodosha Co., Ltd., 2015.

2. Nakase H. To master the optimal therapy for ulcerative colitis. Tokyo: Igakutokangosha Co., Ltd., 2018.

3. Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Mesalazine in the Chemoprevention of Colorectal Cancer

4. Induction of Colonic Regulatory T Cells by Mesalamine by Activating the Aryl Hydrocarbon Receptor

5. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulatory resistin levels in inflammatory bowel disease: a systematic review and meta-analysis;BMC Gastroenterology;2024-03-14

2. Long-term efficacy of vedolizumab therapy in patients with Crohn’s disease;Experimental and Clinical Gastroenterology;2024-01-17

3. Therapeutic Granulomonocytapheresis as a Non-pharmacologic Treatment Option for Inflammatory Bowel Disease: Efficacy Reports on a Wide Age Range and Disease Profile;Cureus;2023-11-16

4. Polysaccharides from Tetrastigma Hemsleyanum Diels et Gilg ameliorated inflammatory bowel disease by rebuilding the intestinal mucosal barrier and inhibiting inflammation through the SCFA-GPR41/43 signaling pathway;International Journal of Biological Macromolecules;2023-10

5. Ligustrazine improves the compensative effect of Akt survival signaling to protect liver Kupffer cells in trauma‐hemorrhagic shock rats;Chemical Biology & Drug Design;2023-08-23